Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-15 |
2024-03 |
-1.09 |
-0.82 |
0.27 |
24.77% |
2024-03-28 |
2023-12 |
-0.86 |
-1.13 |
-0.27 |
-31.40% |
2024-03-28 |
2023-12 |
-0.86 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
-1.41 |
-0.95 |
0.46 |
32.62% |
2023-11-14 |
2023-09 |
-1.41 |
N/A |
N/A |
N/A |
2023-08-14 |
2023-06 |
-1.23 |
-1.53 |
-0.3 |
-24.39% |
Date |
Firm |
Action |
From |
To |
2023-07-26 |
UBS |
Downgrade |
Buy |
Neutral |
2023-07-24 |
Chardan Capital |
Downgrade |
Buy |
Neutral |
2023-07-24 |
Barclays |
Upgrade |
Underweight |
Underweight |
2023-07-24 |
JP Morgan |
Downgrade |
Neutral |
Underweight |
2023-07-23 |
Jefferies |
Downgrade |
Buy |
Hold |
2023-07-23 |
Capital One |
Downgrade |
Overweight |
Equal-Weight |
Date |
Name |
Relation |
Quantity |
Description |
2022-06-05 |
BAKER BROS ADVISORS L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2023-06-15 |
BORGESON JOHN A |
Chief Financial Officer |
178.08K |
Sale |
2023-06-15 |
EHRLICH JASON |
Officer |
61.92K |
Sale |
2020-03-19 |
LEVY RICHARD S |
Director |
1000 |
Purchase |
2020-04-01 |
LIANG HONG |
Officer |
130.17K |
Sale |
2022-12-29 |
PERLROTH VICTOR D |
Chief Executive Officer |
3.45M |
Stock Gift |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Baker Brothers Advisors, LLC |
17.31M |
119.44M |
33.00% |
2023-06-29 |
Blackrock Inc. |
4.51M |
31.10M |
8.59% |
2023-06-29 |
Fairmount Funds Management LLC |
1.99M |
13.70M |
3.78% |
2023-06-29 |
Vanguard Group Inc |
1.63M |
11.24M |
3.11% |
2023-06-29 |
Millennium Management Llc |
1.21M |
8.33M |
2.30% |
2023-06-29 |
ICONIQ Capital, LLC |
1.02M |
7.02M |
1.94% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
980.49K |
6.77M |
1.87% |
2023-08-30 |
iShares Russell 2000 ETF |
744.70K |
1.64M |
1.42% |
2023-05-30 |
BlackRock Advantage Small Cap Core Fund |
478.91K |
2.84M |
0.91% |
2023-06-29 |
Bruce & Co., Inc. |
473.00K |
3.26M |
0.90% |
2023-06-29 |
Vanguard Extended Market Index Fund |
458.13K |
3.16M |
0.87% |
2023-08-30 |
iShares NASDAQ Biotechnology ETF |
345.71K |
760.57K |
0.66% |
Split |
Date |
5 : 1 |
2022-02-23 |